BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36157140)

  • 1. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt.
    Abdelbary MS; Samir R; El-Nahaas SM; Shahin RMH; El-Sayed M; Gaber Y; Tantawi O; Zayed NA; Yosry A
    J Clin Exp Hepatol; 2022; 12(5):1276-1284. PubMed ID: 36157140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
    Serper M; Forde KA; Kaplan DE
    J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
    Tseng CW; Liu WC; Ko PH; Chen YC; Tseng KC; Chang TT
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C.
    Toka B; Köksal AŞ; Dertli R; Şirin G; Fidan S; Ülger Y; Harmandar F; Yıldırım AE; Eminler AT; Asil M; Kayar Y; Bıyık M; Kuran S; Uslan MI; Hülagü S
    Dig Dis; 2022; 40(5):635-643. PubMed ID: 35108715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
    Mücke VT; Mücke MM; Peiffer KH; Weiler N; Welzel TM; Sarrazin C; Zeuzem S; Berger A; Vermehren J
    Aliment Pharmacol Ther; 2017 Aug; 46(4):432-439. PubMed ID: 28627791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
    J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection.
    Liu CH; Liu CJ; Su TH; Fang YJ; Yang HC; Chen PJ; Chen DS; Kao JH
    Open Forum Infect Dis; 2017; 4(1):ofx028. PubMed ID: 28480296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals.
    Lee SW; Lee TY; Yang SS; Peng YC; Yeh HZ; Chang CS
    Gastroenterology Res; 2018 Apr; 11(2):124-129. PubMed ID: 29707079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial.
    Cheng PN; Liu CJ; Chen CY; Tseng KC; Lo CC; Peng CY; Lin CL; Chiu HC; Chiu YC; Chen PJ
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2800-2808. PubMed ID: 34864158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Yanny BT; Latt NL; Saab S; Han S; Choi G; Kramer J; Sahota AK
    J Clin Gastroenterol; 2018; 52(10):908-912. PubMed ID: 29334502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
    Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
    J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy.
    Wani MA; Sodhi JS; Yatoo GN; Shah A; Geelani S; Zargar SA; Gulzar GM; Khan M; Aziz SA
    J Clin Exp Hepatol; 2020; 10(6):590-598. PubMed ID: 33311896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.
    Miyasaka A; Yoshida Y; Suzuki A; Masuda T; Okamoto H; Takikawa Y
    Medicine (Baltimore); 2020 Oct; 99(41):e22650. PubMed ID: 33031326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
    Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
    BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Co-Infection Has Limited Impact on Liver Stiffness Regression in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals.
    Hsu CE; Liu YC; Cheng YT; Jeng WJ; Chien RN; Lin CY; Tai DI; Sheen IS
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy.
    Colombatto P; Palmisano E; Ricco G; Cavallone D; Oliveri F; Coco B; Salvati A; Romagnoli V; Surace L; Vatteroni M; Pistello M; Virdis A; Bonino F; Brunetto MR
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy.
    Majeed NA; Alawad AS; Liem KS; Takyar V; Alter H; Feld JJ; Janssen HLA; Ghany MG
    Dig Dis Sci; 2023 Jul; 68(7):3193-3198. PubMed ID: 37022602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
    Yeh ML; Huang CF; Hsieh MH; Ko YM; Chen KY; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CI; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2017 Oct; 32(10):1754-1762. PubMed ID: 28230928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.